Immunic Inc. traded at $2.24 this Friday January 27th, increasing $0.17 or 8.21 percent since the previous trading session. Looking back, over the last four weeks, Immunic Inc. gained 76.38 percent. Over the last 12 months, its price fell by 80.12 percent. Looking ahead, we forecast Immunic Inc. to be priced at 2.17 by the end of this quarter and at 1.96 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.24
Daily Change
8.21%
Yearly
-80.12%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
BioMarin Pharmaceutical 117.27 0.29 0.25% 36.11%
Dynavax Technologies 11.84 0.06 0.51% -6.03%
Enanta Pharmaceuticals 52.02 0.51 0.99% -11.38%
Intercept Pharmaceuticals 18.40 0.03 0.16% 18.40%
Insmed 21.69 0.23 1.07% 1.36%
Mirati Therapeutics 53.09 2.03 3.98% -53.00%
Omeros 2.70 0.17 6.72% -52.04%
OraSure Technologies 5.29 0.10 1.93% -38.99%
Quidel 86.31 0.14 0.16% -15.17%
Ultragenyx Pharmaceutical 43.72 -0.42 -0.95% -33.76%
Regulus Therapeutics 1.47 -0.06 -3.92% 563.66%
Revance Therapeutics 33.13 -0.75 -2.21% 163.98%
United Therapeutics 259.68 -4.55 -1.72% 29.26%
Immunic Inc. 2.24 0.17 8.21% -80.12%
Xoma 20.85 -0.39 -1.84% 2.01%

Indexes Price Day Year
USND 11622 109.30 0.95% -15.60%
US2000 1911 8.39 0.44% -2.90%

Immunic Inc.
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.